ROGAINE (FOR MEN) Drug Patent Profile

Which patents cover Rogaine (for Men), and when can generic versions of Rogaine (for Men) launch?

Rogaine (for Men) is a drug marketed by Kenvue Brands and is included in one NDA.

The generic ingredient in ROGAINE (FOR MEN) is minoxidil. There is one drug master file entry for this compound. Eighty-six suppliers are listed for this compound. Additional details are available on the minoxidil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rogaine (for Men)

A generic version of ROGAINE (FOR MEN) was approved as minoxidil by WATSON LABS on March 3^rd, 1987.

Summary for ROGAINE (FOR MEN)

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	131
Clinical Trials:	6
DailyMed Link:	ROGAINE (FOR MEN) at DailyMed

Recent Clinical Trials for ROGAINE (FOR MEN)

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ohio State University Comprehensive Cancer Center	Early Phase 1
Loyola University	Phase 2
Cures Within Reach	Phase 2

See all ROGAINE (FOR MEN) clinical trials

Pharmacology for ROGAINE (FOR MEN)

Drug Class	Arteriolar Vasodilator
Physiological Effect	Arteriolar Vasodilation

US Patents and Regulatory Information for ROGAINE (FOR MEN)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kenvue Brands	ROGAINE (FOR MEN)	minoxidil	SOLUTION;TOPICAL	019501-002	Feb 9, 1996		OTC	Yes	Yes

Rogaine for Men Market Dynamics, Patent Position, and Financial Trajectory

Last updated: August 26, 2026

Rogaine for Men is a mature, over-the-counter minoxidil brand with a durable consumer franchise but limited pharmaceutical exclusivity. Kenvue owns the consumer-health portfolio that includes Rogaine following Johnson & Johnson’s consumer-health separation. Brand-level revenue is not publicly disclosed. The financial outlook depends on repeat use, premium pricing for foam products, digital direct-to-consumer distribution, and the brand’s ability to defend share against low-cost generic minoxidil and private-label products.

What is Rogaine for Men and who owns the brand?

Rogaine for Men contains topical minoxidil, an FDA-recognized hair-regrowth active ingredient. U.S. products generally include 5% foam and 5% topical solution. Rogaine was originally commercialized by Upjohn and later became part of Johnson & Johnson’s consumer-health portfolio. Kenvue became an independent public company in 2023 after the separation of Johnson & Johnson’s consumer-health business.[1]

Item	Rogaine for Men
Active ingredient	Minoxidil
Primary U.S. strengths	5% foam and 5% solution
Route	Topical
Regulatory status	Nonprescription OTC
Principal indication	Treatment of hereditary hair loss in men
Current consumer-health owner	Kenvue
Original commercial origin	Upjohn
Orange Book status	Generally not applicable to current OTC products
Biosimilar exposure	None
Generic exposure	High
Brand-level revenue disclosure	Not separately reported

The product is intended for men with common hereditary hair loss, also known as androgenetic alopecia. Rogaine labeling states that continued use is required to maintain regrowth and that results may take several months.[2]

How large is the market for men’s topical minoxidil?

The men’s topical minoxidil market is a mature, high-volume consumer-health category. Its economic structure is different from an innovative prescription drug market because the active ingredient is widely available from generic manufacturers, pharmacies, warehouse clubs, online retailers and telehealth companies.

The principal demand drivers are:

• Aging male populations.
• Rising consumer spending on hair-loss treatment.
• Wider use of digital diagnosis and subscription programs.
• Increased availability of foam products that are easier to apply than liquid formulations.
• Consumer preference for nonprescription treatment before considering oral medicines or hair transplantation.
• Brand recognition associated with Rogaine’s long history and FDA-backed positioning.

The category has a broad price ladder. Rogaine occupies a premium position relative to store-brand minoxidil, while online brands such as Hims and Keeps compete through subscriptions, bundled regimens and digital medical consultations. Costco’s Kirkland Signature minoxidil is a major value competitor in the United States.

Public market reports often publish estimates for the global hair-loss-treatment market, but those estimates usually combine prescription drugs, OTC minoxidil, supplements, devices, clinics and hair-transplant services. They do not provide a reliable standalone revenue figure for Rogaine for Men. Kenvue also does not report Rogaine sales separately in its public filings.[1]

What is Rogaine’s financial trajectory?

Rogaine’s standalone revenue trajectory is not publicly available. Kenvue reports sales by broader geographic and product categories rather than by individual brand. Financial analysis therefore requires a category-based assessment.

Revenue drivers

Rogaine benefits from recurring consumption. Users generally purchase multiple units because treatment must continue to maintain results. That creates a replenishment model with characteristics similar to other chronic-use OTC products.

Foam products can support higher average selling prices than basic liquid minoxidil. They also provide a way for the brand to migrate consumers from low-cost solution products to more convenient formats. Pack sizes, dual-packs and subscription purchases can increase annual revenue per user.

Online sales are another positive factor. Rogaine is available through mass retailers, pharmacies, Amazon and telehealth platforms. Digital channels improve product discoverability and allow subscription-based purchasing, but they also make direct price comparison easier.

Revenue constraints

The principal financial constraint is commoditization. Generic minoxidil is chemically equivalent to branded products for the active ingredient and is often sold at a substantial discount. Retailers can use private-label minoxidil to capture price-sensitive consumers.

The brand also faces adherence limits. Minoxidil does not work for every user, and treatment must be used continuously. Consumers who discontinue because of limited results, irritation or inconvenience reduce lifetime value.

Rogaine is also exposed to substitution from:

• Oral finasteride and dutasteride, including telehealth prescriptions.
• Off-label oral minoxidil.
• Hair-transplant procedures.
• Low-level laser devices.
• Nutritional supplements and cosmetic scalp products.
• Combination regimens marketed by digital health companies.

The likely financial pattern is stable category demand with unit-price pressure. Premium foam and branded trust can protect revenue, but long-term growth is constrained by the absence of product exclusivity and intense retail competition.

What is the FDA regulatory status of Rogaine for Men?

Rogaine for Men is sold in the United States as an OTC hair-regrowth product. Topical minoxidil is included in the FDA framework for OTC external analgesic and hair-growth-related drug products, depending on the specific formulation and regulatory pathway. Current products are marketed under established FDA OTC requirements and labeling conditions.[2][3]

The key regulatory characteristics are:

Regulatory issue	Status
Prescription requirement	No for standard topical Rogaine products
FDA-approved active ingredient	Yes, topical minoxidil
OTC availability	Yes
5% men’s foam	Widely marketed OTC
5% men’s solution	Widely marketed OTC
Pediatric use	Not intended for children under the labeled age threshold
Chronic treatment	Yes, with continued use required
Prescription generic approval pathway	Not the principal pathway for current OTC products

Rogaine’s label limits the product to hereditary hair loss and includes warnings concerning chest pain, rapid heartbeat, dizziness, unwanted facial hair and scalp irritation.[2] The label also warns against use by women for the men’s product and against use when hair loss is sudden, patchy or unexplained.

What patents protect Rogaine for Men?

No active foundational patent appears to provide meaningful exclusivity for branded topical minoxidil in the United States. Minoxidil’s use for hair growth has been established for decades, and the original pharmaceutical and formulation patents have expired or no longer create a material barrier to generic competition.

Rogaine’s current protection is primarily commercial rather than patent-based:

• Brand name and trademark rights.
• Consumer recognition.
• Retail placement.
• Formulation presentation.
• Packaging and product-line management.
• Marketing claims supported by the FDA OTC framework.
• Distribution relationships.
• Customer data from online channels.

Because Rogaine is an OTC product rather than a current prescription product, it generally does not have a conventional Orange Book patent position comparable to a new prescription medicine. The absence of an Orange Book listing removes the principal mechanism used by branded prescription companies to trigger Paragraph IV litigation against ANDA applicants.

Are Rogaine’s formulation patents still important?

Formulation and delivery improvements can support differentiation, but they do not restore broad active-ingredient exclusivity. Rogaine’s 5% foam may provide consumer benefits involving application feel, drying time and cosmetic acceptability. Those characteristics can support premium pricing even when competing products contain the same active ingredient.

Any formulation-specific patent protection would need to be assessed patent by patent and jurisdiction by jurisdiction. The commercial barrier is limited because competing manufacturers can sell liquid or foam minoxidil without copying protected branding, packaging or proprietary manufacturing details.

Does Rogaine face Paragraph IV challenges?

Rogaine is not exposed to a conventional Paragraph IV challenge in the same way as an active prescription NDA product. Paragraph IV litigation applies to patents listed in the FDA Orange Book and challenged by an abbreviated new drug application applicant.

For current OTC topical minoxidil products:

• There is no central Orange Book patent estate driving generic-entry timing.
• Generic and store-brand competition is already established.
• There is no meaningful 30-month-stay strategy protecting the brand from minoxidil competitors.
• Competitive entry occurs through OTC compliance, private-label manufacturing and retail distribution rather than patent litigation.

This structure makes price competition more important than patent litigation.

What is the Orange Book status of Rogaine?

Rogaine for Men does not have a commercially significant Orange Book exclusivity position. The product is marketed as an OTC treatment, and the core minoxidil market is already populated by generic and private-label products.

The Orange Book therefore does not provide a reliable forecast for Rogaine’s loss of exclusivity. The relevant commercial date is not a future patent cliff. Rogaine’s loss of exclusivity occurred through the historical expiration of foundational rights and the broad adoption of generic minoxidil.

When did Rogaine lose exclusivity?

Rogaine lost meaningful market exclusivity years ago as topical minoxidil became available from generic manufacturers and was incorporated into the OTC market. No future patent-expiration event is expected to produce a new wave of generic entry comparable to the launch of a newly generic prescription drug.

The brand continues to sell because exclusivity and brand value are different assets. Rogaine can command a premium through recognition, perceived reliability and convenience, even though the active ingredient is commoditized.

Which companies are challenging Rogaine commercially?

Rogaine’s main competitors are not patent challengers. They are manufacturers, retailers and digital health companies competing for the same consumer.

Competitor type	Representative examples	Competitive mechanism
Private-label OTC	Kirkland Signature and pharmacy brands	Lower price
Branded OTC	Equate and other retailer brands	Retail access and value
Digital health	Hims, Keeps and similar platforms	Subscription, consultation and bundled therapy
Prescription alternatives	Finasteride and dutasteride providers	Different mechanism and treatment positioning
Procedure providers	Hair-transplant clinics	Permanent or procedural treatment
Device companies	Low-level laser products	Non-drug treatment modality
Supplement brands	Nutraceutical hair-loss products	Consumer wellness positioning

Digital providers can reduce Rogaine’s customer-acquisition advantage by bundling topical minoxidil with finasteride, oral minoxidil or supplements. That creates a broader competitive threat than another topical minoxidil label because the consumer is purchasing a treatment program rather than a single product.

What patent litigation and settlements affect Rogaine?

No material current Rogaine-specific patent litigation or settlement is central to the commercial outlook based on publicly reported Kenvue disclosures and the OTC status of the product.[1] The key legal risks are more likely to involve:

• Advertising and substantiation of hair-regrowth claims.
• Trademark enforcement.
• Counterfeit products on online marketplaces.
• Product-liability claims.
• Regulatory compliance for compounded or telehealth-distributed minoxidil.
• Competition involving packaging or trade dress.

There is no apparent settlement-driven generic launch schedule for Rogaine. Market access is governed primarily by product compliance, manufacturing capacity and retailer acceptance.

How strong is the Rogaine patent estate?

Rogaine’s patent estate is weak as a barrier to generic entry but valuable as part of a wider brand portfolio.

Patent-estate dimension	Assessment
Active-ingredient protection	Expired or commercially ineffective
Orange Book protection	Limited or not applicable
Formulation protection	Narrow and product-specific
Manufacturing protection	Possible process know-how, but not a broad market barrier
Trademark protection	Stronger than patent protection
Regulatory exclusivity	No meaningful current exclusivity
Generic-entry barrier	Low
Brand pricing power	Moderate, strongest for foam and trusted retail channels

The most defensible assets are trademarks, packaging, consumer awareness and distribution. Manufacturing know-how can improve quality and supply reliability, but topical minoxidil is not generally considered a technically difficult product to manufacture at commercial scale.

What generic launch risks exist for Rogaine?

Generic launch risk is already embedded in the business. The relevant question is not whether generic minoxidil will enter, but how much additional share and pricing pressure it will create.

The main scenarios are:

Base case

Rogaine retains a premium branded position while generic and private-label products capture price-sensitive users. Revenue remains broadly stable or grows modestly through foam, online sales and repeat purchases. Gross margins face pressure from promotions and retailer bargaining.

Downside case

Retailers expand private-label shelf space, online marketplaces intensify price competition and digital health companies bundle cheaper minoxidil with other treatments. Rogaine loses unit share and must increase promotional spending.

Upside case

Kenvue improves digital distribution, expands foam adoption, increases subscription replenishment and preserves consumer trust. Revenue growth comes from mix and price rather than large volume expansion.

How does Rogaine compare with prescription hair-loss drugs?

Rogaine has a lower regulatory burden and a broader consumer base than prescription alternatives. It also has weaker exclusivity and lower switching costs.

Attribute	Rogaine for Men	Finasteride	Oral minoxidil
Status	OTC topical	Prescription	Typically off-label for hair loss
Active ingredient	Minoxidil	Finasteride	Minoxidil
Main differentiation	Brand, convenience, foam	Different mechanism	Systemic exposure
Patent barrier	Minimal	Product- and jurisdiction-dependent	Limited for hair-loss use
Consumer access	Broad	Requires prescription in many markets	Requires clinician involvement
Main commercial risk	Generic price competition	Safety perception and generic substitution	Off-label safety and regulatory scrutiny

Rogaine remains relevant because consumers often begin with a topical OTC product before considering prescription therapy. Digital providers can convert that initial demand into combination treatment, potentially reducing Rogaine’s role as a standalone product while increasing its role within a broader regimen.

What is the geographic coverage of Rogaine?

Rogaine has broad international recognition, but the brand name, regulatory status, concentrations and ownership arrangements can vary by country. In some markets, topical minoxidil is sold under alternative brand names or by local generic manufacturers.

Geographic risks include:

• Different OTC and prescription classifications.
• Local trademark ownership.
• Country-specific labeling requirements.
• Varying patent treatment for formulations and methods of use.
• Parallel imports and online cross-border sales.
• Local pharmacy and e-commerce concentration.

The United States remains commercially important because of the scale of OTC retail, subscription commerce and consumer familiarity with the Rogaine name. International revenue is not separately reported by product.

What manufacturing and intellectual-property barriers affect Rogaine?

Manufacturing barriers are modest relative to biologics, sterile injectables or complex delivery systems. Minoxidil solution is comparatively straightforward to produce. Foam products require more specialized packaging, propellant and filling capabilities, which can create quality-control and supply-chain requirements but do not prevent capable competitors from entering.

The main operational risks are:

• Availability of active pharmaceutical ingredient.
• Aerosol and foam packaging capacity.
• Stability and preservative performance.
• Product consistency across contract manufacturers.
• Retail inventory management.
• Counterfeit control in online channels.
• Compliance with OTC labeling and manufacturing standards.

Kenvue’s scale and established consumer-health distribution provide advantages, but those advantages do not create a durable legal monopoly.

Key Takeaways

• Rogaine for Men is a mature OTC minoxidil brand owned by Kenvue.
• Brand-level revenue and profit are not separately disclosed.
• The financial trajectory is likely driven by repeat purchases, foam mix, online subscriptions and premium pricing.
• Generic and private-label minoxidil create persistent price and share pressure.
• The core minoxidil patent estate no longer provides meaningful market exclusivity.
• Rogaine has no conventional future patent cliff because generic competition is already established.
• Paragraph IV litigation and Orange Book strategy are not central to the product’s outlook.
• Brand, trademark, retail access and consumer trust are more important than patent protection.
• Digital health companies create competitive pressure by bundling minoxidil with finasteride, oral minoxidil and other treatments.
• The most likely long-term outcome is a resilient but low-growth branded OTC business with margin pressure and continued premium positioning for foam products.

FAQs

Is Rogaine for Men still profitable after generic minoxidil entry?

The brand can remain profitable because users pay for recognition, convenience and perceived reliability. Profitability is constrained by generic pricing, retailer promotions and customer-acquisition costs.

Can a company launch a generic version of Rogaine without a patent settlement?

Yes. Generic and private-label minoxidil products can compete through the applicable OTC regulatory framework without waiting for a Rogaine patent settlement.

Does Rogaine have exclusivity for its 5% foam?

Rogaine may have product-specific branding, packaging or formulation rights, but those rights do not create broad exclusivity over 5% topical minoxidil.

Are Hims and Keeps taking sales from Rogaine?

They can divert sales by offering minoxidil through subscriptions and by combining it with prescription or off-label treatments. Their competitive effect is strongest among consumers seeking a complete digital treatment program.

What is the biggest investment risk for the Rogaine brand?

The largest risk is gradual commoditization. Generic price competition, private-label expansion and digital treatment bundles can reduce Rogaine’s unit share and force higher promotional spending even if overall hair-loss-treatment demand remains stable.

References

1. Kenvue Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.

2. Kenvue Inc. (2023). Rogaine for Men extra strength minoxidil topical aerosol, 5%: Drug facts label. U.S. Food and Drug Administration labeling database.

3. U.S. Food and Drug Administration. (2023). Over-the-counter monograph and regulatory information for topical hair-growth products containing minoxidil. FDA.